Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma -

Key Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory LBCL.Durable responses were associated wit

123456

The Fellow on Call: The Heme/Onc Podcast

While we await the overall survival data for ZUMA-7, the mature ZUMA-1 data shows the curative potential of Axi-cel (Yescarta) for relapsed/refractory DLBCL.

Takeaway from TFOC:
– Best response CR in 59% –> many will still relapse!
– Long term CR in 30% –> CURE!

Read the full article here

See more from The Fellow on Call: The Heme/Onc Podcast